$160 Million is the total value of Memorial Sloan Kettering Cancer Center's 6 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RPRX | ROYALTY PHARMA PLC | $96,878,000 | -11.8% | 2,680,644 | 0.0% | 60.36% | -16.0% | |
| GDX | VANECK ETF TRUSTgold miners etf | $21,764,000 | -13.3% | 738,500 | 0.0% | 13.56% | -17.3% | |
| New | CARIBOU BIOSCIENCES INC | $16,093,000 | – | 674,196 | +100.0% | 10.03% | – | |
| ORIC | ORIC PHARMACEUTICALS INC | $12,594,000 | +18.2% | 602,272 | 0.0% | 7.85% | +12.7% | |
| ILMN | New | ILLUMINA INC | $6,975,000 | – | 17,196 | +100.0% | 4.35% | – |
| YMAB | Y-MABS THERAPEUTICS INC | $6,191,000 | -15.6% | 216,916 | 0.0% | 3.86% | -19.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANECK VECTORS ETF TR | 12 | Q3 2023 | 80.9% |
| ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 14.8% |
| Y-MABS THERAPEUTICS INC | 12 | Q3 2023 | 9.6% |
| CARIBOU BIOSCIENCES INC | 8 | Q2 2023 | 19.5% |
| ILLUMINA INC | 8 | Q2 2023 | 4.4% |
| ROYALTY PHARMA PLC | 6 | Q1 2022 | 75.6% |
View Memorial Sloan Kettering Cancer Center's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Y-mAbs Therapeutics, Inc. | February 14, 2020 | 257,517 | 0.6% |
| Actinium Pharmaceuticals, Inc. | February 13, 2018 | 1,230,954 | 1.5% |
| Cactus Ventures, Inc. | January 18, 2013 | 5,702,387 | 34.7% |
View Memorial Sloan Kettering Cancer Center's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
View Memorial Sloan Kettering Cancer Center's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.